Progranulin protects against amyloid β 2 deposition and toxicity in Alzheimer's disease mouse models

Nature Medicine

Volumn 20, Issue 10, 2014, Pages 1157-1164

  Minami, S Sakura ^a,b   Min, Sang Won ^a,b   Krabbe, Grietje ^a,b   Wang, Chao ^a,b   Zhou, Yungui ^a   Asgarov, Rustam ^c   Li, Yaqiao ^a   Martens, Lauren H ^d   Elia, Lisa P ^a   Ward, Michael E ^a,b   Mucke, Lennart ^a,b   Farese, Robert V ^b,d   Gan, Li ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PROGRANULIN; RECOMBINANT GROWTH FACTOR; RECOMBINANT PROGRANULIN; UNCLASSIFIED DRUG; GRN PROTEIN, HUMAN; GRN PROTEIN, MOUSE; SIGNAL PEPTIDE;

ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE EXACERBATION; GENE OVEREXPRESSION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MALE; MEDIATOR; MICROGLIA; MOUSE; MOUSE MODEL; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIAL MEMORY; ANIMAL; BRAIN; C57BL MOUSE; COGNITION; DEFICIENCY; DISEASE MODEL; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INNATE IMMUNITY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; TRANSGENIC MOUSE; UPREGULATION;

LENTIVIRUS; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; PHAGOCYTOSIS; PLAQUE, AMYLOID; RATS; UP-REGULATION;

EID: 84921968828     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3672     Document Type: Article

References (63)

1. Daniel, R., He, Z., Carmichael, K.P., Halper, J., Bateman, A. Cellular localization of gene expression for progranulin. J. Histochem. Cytochem. 48, 999-1009 (2000).
2. Daniel, R., Daniels, E., He, Z., Bateman, A. Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev. Dyn. 227, 593-599 (2003).
3. Petkau, T.L. et al. Progranulin expression in the developing and adult murine brain. J. Comp. Neurol. 518, 3931-3947 (2010).
4. Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919 (2006).
5. Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924 (2006).
6. Gass, J. et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum. Mol. Genet. 15, 2988-3001 (2006).
7. Yin, F. et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 207, 117-128 (2010).
8. Petkau, T.L. et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol. Dis. 45, 711-722 (2012).
9. Yin, F. et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 24, 4639-4647 (2010).
10. Filiano, A.J. et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 33, 5352-5361 (2013).
11. Martens, L.H. et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J. Clin. Invest. 122, 3955-3959 (2012).
12. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
13. McGeer, P.L., McGeer, E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21, 195-218 (1995).
14. Ilieva, H., Polymenidou, M., Cleveland, D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761-772 (2009).
15. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015 (2006).
16. McGeer, P.L., Rogers, J., McGeer, E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis. 9, 271-276 (2006).
17. Frank-Cannon, T.C., Alto, L.T., McAlpine, F.E., Tansey, M.G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4, 47 (2009).
18. Seshadri, S. et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. J. Am. Med. Assoc. 303, 1832-1840 (2010).
19. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011).
20. Brouwers, N. et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71, 656-664 (2008).
21. Cortini, F. et al. Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur. J. Neurol. 15, 1111-1117 (2008).
22. Viswanathan, J. et al. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B, 747-750 (2009).
23. Kelley, B.J. et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch. Neurol. 67, 171-177 (2010).
24. Perry, D.C. et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 70, 774-778 (2013).
25. Pereson, S. et al. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J. Pathol. 219, 173-181 (2009).
26. Gliebus, G., Rosso, A., Lippa, C.F. Progranulin and ?-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. Am. J. Alzheimers Dis. Other Demen. 24, 456-460 (2009).
27. Mucke, L. et al. High-level neuronal expression of a? 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
28. Oakley, H. et al. Intraneuronal ?-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006).
29. Chin, J. et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25, 9694-9703 (2005).
30. Palop, J.J. et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100, 9572-9577 (2003).
31. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Forster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).
32. Hickman, S.E., Allison, E.K., El Khoury, J. Microglial dysfunction and defective ?-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 8354-8360 (2008).
33. Pickford, F. et al. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am. J. Pathol. 178, 284-295 (2011).
34. Chen, J. et al. SIRT1 protects against microglia-dependent amyloid-? toxicity through inhibiting NF-?B signaling. J. Biol. Chem. 280, 40364-40374 (2005).
35. Yin, F. et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 207, 117-128 (2010).
36. Walsh, D.M. et al. Naturally secreted oligomers of amyloid ? protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
37. Eimer, W.A., Vassar, R. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal A?42 accumulation and caspase-3 activation. Mol. Neurodegener. 8, 2 (2013).
38. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., Wirths, O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A? aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, 196 e29-40 (2012).
39. Suh, H.S., Choi, N., Tarassishin, L., Lee, S.C. Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). PLoS ONE 7, e35115 (2012).
40. Cenik, B., Sephton, C.F., Kutluk Cenik, B., Herz, J., Yu, G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J. Biol. Chem. 287, 32298-32306 (2012).
41. Smith, K.R. et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102-1107 (2012).
42. Ahmed, Z. et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 177, 311-324 (2010).
43. Filiano, A.J. et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 33, 5352-5361 (2013).
44. Ottis, P. et al. Human and rat brain lipofuscin proteome. Proteomics 12, 2445-2454 (2012).
45. Brunk, U.T., Terman, A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic. Biol. Med. 33, 611-619 (2002).
46. Laird, A.S. et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 5, e13368 (2010).
47. Ryan, C.L. et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 10, 130 (2009).
48. Xu, J. et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol Aging 32, 2326 e5-16 (2011).
49. Kao, A.W. et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc. Natl. Acad. Sci. USA 108, 4441-4446 (2011).
50. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-845 (2010).
51. Butovsky, O. et al. Identification of a unique TGF-?-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131-143 (2014).
52. Hickman, S.E. et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896-1905 (2013).
53. Pan, X.D. et al. Microglial phagocytosis induced by fibrillar ?-amyloid is attenuated by oligomeric ?-amyloid: implications for Alzheimer's disease. Mol. Neurodegener. 6, 45 (2011).
54. Koenigsknecht, J., Landreth, G. Microglial phagocytosis of fibrillar ?-amyloid through a ?1 integrin-dependent mechanism. J. Neurosci. 24, 9838-9846 (2004).
55. Mueller-Steiner, S. et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714 (2006).
56. Sun, B. et al. Cystatin C-cathepsin B axis regulates amyloid ? levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247-257 (2008).
57. Johnson-Wood, K. et al. Amyloid precursor protein processing and A?42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 1550-1555 (1997).
58. Koo, E.H., Squazzo, S.L. Evidence that production and release of amyloid ?-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386-17389 (1994).
59. Krabbe, G. et al. Functional impairment of microglia coincides with ?-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE 8, e60921 (2013).
60. Sun, B., Gan, L. Manipulation of gene expression in the central nervous system with lentiviral vectors. Methods Mol. Biol. 670, 155-168 (2011).
61. Hughes, R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 28, 497-505 (2004).
62. Laird, N.M., Ware, J.H. Random-effects models for longitudinal data. Biometrics 38, 963-974 (1982).
63. Altman, D.G., Bland, J.M. How to obtain the P value from a confidence interval. BMJ 343, d2304 (2011).